TWI319765B - 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders - Google Patents
1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disordersInfo
- Publication number
- TWI319765B TWI319765B TW091107023A TW91107023A TWI319765B TW I319765 B TWI319765 B TW I319765B TW 091107023 A TW091107023 A TW 091107023A TW 91107023 A TW91107023 A TW 91107023A TW I319765 B TWI319765 B TW I319765B
- Authority
- TW
- Taiwan
- Prior art keywords
- triazaspiro
- orl
- decan
- treatment
- receptor mediated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28272201P | 2001-04-10 | 2001-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI319765B true TWI319765B (en) | 2010-01-21 |
Family
ID=23082838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW091107023A TWI319765B (en) | 2001-04-10 | 2002-04-09 | 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
Country Status (11)
Country | Link |
---|---|
US (2) | US6777421B2 (zh) |
EP (1) | EP1392687B1 (zh) |
JP (1) | JP4601254B2 (zh) |
AR (1) | AR035820A1 (zh) |
AU (1) | AU2008229844B2 (zh) |
CA (1) | CA2443868C (zh) |
MX (1) | MXPA03009239A (zh) |
MY (1) | MY124844A (zh) |
NZ (1) | NZ570181A (zh) |
TW (1) | TWI319765B (zh) |
WO (1) | WO2002083673A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022558A2 (en) | 2002-09-09 | 2004-03-18 | Janssen Pharmaceutica, N.V. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
AR046756A1 (es) * | 2003-12-12 | 2005-12-21 | Solvay Pharm Gmbh | Derivados de hidronopol como agonistas de receptores orl-1 humanos. |
US20060178390A1 (en) * | 2004-08-02 | 2006-08-10 | Alfonzo Jordan | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
US7235459B2 (en) * | 2004-08-31 | 2007-06-26 | Micron Technology, Inc. | Methods of forming trench isolation in the fabrication of integrated circuitry, methods of fabricating memory circuitry, integrated circuitry and memory integrated circuitry |
DE102005038141A1 (de) * | 2005-08-12 | 2007-02-15 | Grünenthal GmbH | Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate |
WO2008067167A1 (en) * | 2006-11-28 | 2008-06-05 | Janssen Pharmaceutica N.V. | Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
CN101679430B (zh) * | 2007-04-09 | 2013-12-25 | 詹森药业有限公司 | 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物 |
WO2010037081A1 (en) * | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
EP2738170B1 (en) | 2011-07-29 | 2017-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
TW201712012A (zh) | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | 2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物 |
EP3317279B1 (en) * | 2015-07-03 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Triaza-spirodecanones as ddr1 inhibitors |
RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
CA3076476A1 (en) | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
CA3080677A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
EP3704120B1 (en) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Heterocyclic compounds as prmt5 inhibitors |
CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
IT201800007580A1 (it) * | 2018-07-27 | 2020-01-27 | Maria Cecilia Hospital Spa | Composti 1,3,8-triazaspiro e loro uso come medicamenti |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US439853A (en) * | 1890-11-04 | Clothes-drier | ||
US3155699A (en) | 1960-03-30 | 1964-11-03 | Mobay Chemical Corp | Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content |
US3155670A (en) * | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
US3161644A (en) * | 1962-06-22 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-benzyl-4-substituted piperidines |
US3238216A (en) * | 1963-06-20 | 1966-03-01 | Res Lab Dr C Janssen N V | Substituted 1, 3, 8-triaza-spiro (4, 5) decanes |
US3629267A (en) | 1968-10-28 | 1971-12-21 | Smith Kline French Lab | Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione |
US4020072A (en) * | 1976-05-04 | 1977-04-26 | E. R. Squibb & Sons, Inc. | 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines |
US4526896A (en) | 1978-12-26 | 1985-07-02 | Riker Laboratories, Inc. | Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof |
JPS57212180A (en) * | 1981-06-19 | 1982-12-27 | Yoshitomi Pharmaceut Ind Ltd | Tetrahydrofuran(thiophene) compound |
CN1168719C (zh) * | 1996-03-29 | 2004-09-29 | 辉瑞大药厂 | 6-苯基吡啶-2-基胺衍生物以及药物组合物和用途 |
CA2226058C (en) | 1997-01-30 | 2008-01-29 | F. Hoffmann-La Roche Ag | 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives |
JP2002515503A (ja) | 1998-05-18 | 2002-05-28 | ノボ ノルディスク アクティーゼルスカブ | オピオイド受容体のサブタイプへの高い親和性を有する新規1,3,8−トリアザスピロ〔4,5〕デカノン |
US6277991B1 (en) | 1998-05-18 | 2001-08-21 | Novo Nordisk A/S | 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
EP1087770A4 (en) | 1998-06-15 | 2001-11-14 | Merck & Co Inc | INHIBITORS OF PRENYL PROTEIN TRANSFERASE |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
DE69923744T2 (de) * | 1998-10-23 | 2006-02-23 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten |
TR200101412T2 (tr) | 1998-11-20 | 2001-10-22 | Smithkline Beecham S.P.A. | Yeni bileşikler. |
JP2000169476A (ja) * | 1998-12-09 | 2000-06-20 | Banyu Pharmaceut Co Ltd | 4−オキソイミダゾリジン−5−スピロ−含窒素複素環式化合物 |
AU1691500A (en) * | 1998-12-24 | 2000-07-31 | Meiji Seika Kaisha Ltd. | Remedies for pain |
AU1382901A (en) * | 1999-11-17 | 2001-05-30 | Novo Nordisk A/S | Novel triazaspirodecanones with high affinity for opioid receptor subtypes |
EP1537110B1 (en) * | 1999-12-06 | 2007-01-17 | Euro-Celtique, S.A. | Triazospiro compounds having nociceptin receptor affinity |
-
2002
- 2002-04-05 MX MXPA03009239A patent/MXPA03009239A/es active IP Right Grant
- 2002-04-05 JP JP2002581428A patent/JP4601254B2/ja not_active Expired - Fee Related
- 2002-04-05 EP EP02721678.7A patent/EP1392687B1/en not_active Expired - Lifetime
- 2002-04-05 WO PCT/US2002/010736 patent/WO2002083673A1/en active Application Filing
- 2002-04-05 CA CA2443868A patent/CA2443868C/en not_active Expired - Fee Related
- 2002-04-05 NZ NZ570181A patent/NZ570181A/en not_active IP Right Cessation
- 2002-04-05 US US10/117,674 patent/US6777421B2/en not_active Expired - Lifetime
- 2002-04-09 TW TW091107023A patent/TWI319765B/zh not_active IP Right Cessation
- 2002-04-09 MY MYPI20021287A patent/MY124844A/en unknown
- 2002-04-09 AR ARP020101302A patent/AR035820A1/es unknown
-
2004
- 2004-08-02 US US10/909,858 patent/US7053101B2/en not_active Expired - Lifetime
-
2008
- 2008-10-09 AU AU2008229844A patent/AU2008229844B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2008229844A1 (en) | 2008-10-30 |
AR035820A1 (es) | 2004-07-14 |
JP4601254B2 (ja) | 2010-12-22 |
AU2008229844B2 (en) | 2012-05-31 |
WO2002083673A1 (en) | 2002-10-24 |
EP1392687B1 (en) | 2017-02-01 |
US20030109539A1 (en) | 2003-06-12 |
MY124844A (en) | 2006-07-31 |
EP1392687A1 (en) | 2004-03-03 |
MXPA03009239A (es) | 2004-11-12 |
JP2004525967A (ja) | 2004-08-26 |
CA2443868C (en) | 2011-01-25 |
US20050004154A1 (en) | 2005-01-06 |
US6777421B2 (en) | 2004-08-17 |
US7053101B2 (en) | 2006-05-30 |
CA2443868A1 (en) | 2002-10-24 |
NZ570181A (en) | 2010-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL377047A1 (pl) | Hydroksyalkilopodstawione pochodne 1,3,8-triazaspiro [4,5]-dekan-4-onu przydatne w leczeniu zaburzeń, w których pośredniczy receptor ORL-1 | |
TWI319765B (en) | 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders | |
AU6751301A (en) | 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists | |
HK1064669A1 (en) | Substituted 1-oxy-2,8-diaza-spiro Ä4,5Üdec-2-ene derivatives as medicaments for the treatment of pain. | |
AU2003249983A1 (en) | Piperidines useful for the treatment of central nervous system disorders | |
PL373626A1 (en) | Treatment for central nervous system disorders | |
IL160707A0 (en) | 1, 8-naphthyridine derivatives as antidiabetics | |
PT2260850T (pt) | Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento | |
AU2002310768A1 (en) | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain | |
IL159350A0 (en) | Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury | |
AP2004002981A0 (en) | Method for the preparation of hexahydro-furo [2,3-B]furan-3-o1. | |
HUP0202202A3 (en) | Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof | |
AU8187701A (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders | |
IL147977A0 (en) | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain | |
AU2003265589A8 (en) | Process for the preparation of 1,1,1,2,2-pentafluoroethane | |
HUP0202253A3 (en) | Selective iglur5 receptor antagonists for the treatment of migraine | |
AU6910600A (en) | Methods for the treatment of mental disorders | |
AU3086900A (en) | Device for the complex treatment of disorders of the prostate | |
EE04905B1 (et) | Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks | |
MXPA03008965A (es) | Uso de compuestos de imidazo [1,2-a]-piridinas sustituidas como medicamentos. | |
AP2005003196A0 (en) | Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor. | |
HUP0300569A3 (en) | Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders and pharmaceutical compositions containing the compounds | |
HK1057332A1 (en) | Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders | |
AU2003230758A1 (en) | 5h-benzo(4,5)cyclohepta(1,2-b)pyridine nmda/nr2b antagonists | |
MXPA03001472A (es) | Compuestos para el tratamiento de trastornos adictivos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |